United States Supreme Court
Merck v. Integra Lifesciences, 03-1237
The use of patented compounds in preclinical studies is protected under 37 U.S.C. section 271(e)(1) as long as there is a reasonable basis to believe that the compound tested could be the subject of an FDA submission and the experiments will produce the types of information relevant to a new drug application.
Appellate Information
- Decided 06/13/2005
- Published 06/13/2005
Judges
Court
- United States Supreme Court